BY MARKETWIRE
-
Genmab’s moment of truth nears: Jyske Bank sees potential for big price reaction
Genmab will certainly quickly learn if its companion Johnson & Johnson picks to proceed servicing the medicine prospect Hexabody-CD38– a possible follower to significant…
-
Investment bank sees potential in Zealand Pharma: 2025 budget has merit
Zealand Pharma has actually allocated internet operating expense in the series of DKK 2,000-2,500 m in 2025.
-
Analyst: New partnership paves way for Bavarian Nordic to meet future demand
Sydbank’s senior analyst says it alerts confidence within the industrial potential of the vaccine, which is predicted to be accepted quickly in Europe and has already been given th…
-
Trump plans to impose 25% import tariffs on pharmaceuticals
Donald Trump has actually currently made a decision to enforce 25% tolls on steel and light weight aluminum to work in March.
-
Zealand Pharma has significantly increased R&D costs in search of new obesity drug
In 2014, Zealand Pharma’s operating expense completed DKK 1,327 m (USD 185.72 m).
-
Ambu endoscope gains new applications after CE marking
The CE mark will certainly allow health center personnel to utilize the Ambus endoscope for brand-new treatments, consisting of the elimination of big and difficult kidney rocks.
-
ALK on US tariff threat: It’s only a minor issue for us
On Tuesday, United States Head Of State Donald Trump once more advised of tolls on drugs and various other items.
-
Analyst: US approval of copy insulin shouldn’t shake Novo Nordisk
Final week, French drugmaker Sanofi obtained approval for its product Merilog on the US market.
-
GN nominates two new board members as one resigns
The proposition requires GN’s board being increased from 6 to 7 participants.
-
Lundbeck awarded accelerated treatment for MSA in the US
Lundbeck will certainly get continuous responses from the FDA, which will certainly likewise supply extensive assistance on just how to successfully create the medicine.
